Repatha SureClick *
Pharmacy Only: Prescription

  • Company:

    Amgen Ireland Ltd
  • Status:

    No Recent Update
  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)
  • Active Ingredient(s):

    *Additional information is available within the SPC or upon request to the company

Updated on 21 June 2022

File name

62b197e45b806.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 06 April 2022

File name

ie_xi_repatha_approved_smpc_v57_HauserOLE_1649284764.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 29 March 2022

File name

ie_xi_repatha_approved_smpc_v57_HauserOLE_1648592660.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 12 January 2022

File name

ie_xi_repatha_approved_pil_pfp_v49_1642011780.pdf

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - use in children/adolescents

Free text change information supplied by the pharmaceutical company

New information on heterozygous familial hypercholesterolaemia) Homozygous familial hypercholesterolaemia  in paediatric patients aged 10 years and over .

Updated on 12 January 2022

File name

ie_xi_repatha_approved_spc_v49_1642010834.pdf

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.1, 4.2, 4.8, 5.1 and 5.2 Therapeutic Indications - New information on: Hypercholesterolaemia and mixed dyslipidaemia, Homozygous familial hypercholesterolaemia in  paediatric population aged 10 years and over.

 

 

 

Updated on 27 April 2021

File name

ie_xi_repatha_approved_spc_pbrer10_1619520733.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable effects

Addition of headache as common side effect

Section 10 Date of reviison of the text

April 2021

Updated on 27 April 2021

File name

ie_xi_repatha_approved_pil_pbrer10_1619520634.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Section 4 - Possible side effects

Addition of headache as a common side effect

Date of revision April 2021

Updated on 13 April 2021

File name

en_repatha_approved_pi_v47 (1)_1618318886.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

SPC

 

Section 4.4 Special warnings and precautions for use

This medicinal product contains less than 1 mmol sodium (23mg) per dose, i.e. it is that is to say essentially “sodium-free”

Section 4.8 Undesirable Effects

Myalgia added as common adverse event

Section 10 Date of revision of the text

Feb 2021

PIL

 

Section 2 What you need to know before you use Repatha

In order to improve the traceability of this medicine, your doctor or pharmacist should record the name and the lot number of the product you have been given in your patient file. You may also wish to make a note of these details in case you are asked for this information in the future.

Section 4 Side Effects

Muscle pain added as common side effect

Instructions for Use

Numerous updates made to the text in this section to clarify the steps.

Date of revision of the text

Feb 2021

Updated on 13 April 2021

File name

en_repatha_approved_pi_v47 (1)_1618318798.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 13 April 2021

File name

en_repatha_approved_Pil_v47_1617115770.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

SPC

 

Section 4.4 Special warnings and precautions for use

This medicinal product contains less than 1 mmol sodium (23mg) per dose, i.e. it is that is to say essentially “sodium-free”

Section 4.8 Undesirable Effects

Myalgia added as common adverse event

Section 10 Date of revision of the text

Feb 2021

PIL

 

Section 2 What you need to know before you use Repatha

In order to improve the traceability of this medicine, your doctor or pharmacist should record the name and the lot number of the product you have been given in your patient file. You may also wish to make a note of these details in case you are asked for this information in the future.

Section 4 Side Effects

Muscle pain added as common side effect

Instructions for Use

Numerous updates made to the text in this section to clarify the steps.

Date of revision of the text

Feb 2021

Updated on 30 March 2021

File name

en_repatha_approved_spc_v47_1617115879.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 30 March 2021

File name

en_repatha_approved_Pil_v47_1617115770.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 15 December 2020

File name

en_repatha_approved_spc_v43_1608024441.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The following sections have been updated:

Section 5.1 Pharmacodynamic properties - Addition of EVOPACS a single country, multicenter, double-blind, randomized, placebo-controlled, 8-week study.

Section 10 Date of revision of the text – Oct 2020

Updated on 16 April 2020

File name

en_repatha_approved_pil_r40_1587046619.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision
  • Removal of Black Inverted Triangle

Free text change information supplied by the pharmaceutical company

PIL

The black triangle has been removed from Repatha

 

Section 2 Warnings and Precautions

Warnings and precautions

The needle cover of the glass pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions.

 

Pregnancy and breast-feeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Date of revision of the text

April 2020

Updated on 16 April 2020

File name

en_repatha_approved_spc_r40_1587046462.pdf

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 6.6 - Special precautions for disposal and other handling
  • Change to section 10 - Date of revision of the text
  • Removal of Black Inverted Triangle

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

SPC

The black triangle has been removed from Repatha

Repatha has been by evolocumab throughout the SPC

 

Section 4.4 Special Warnings and Precautions

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded

 

Repatha 140 mg solution for injection in pre-filled syringe

The needle cover of the glass pre-filled syringe is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions.

 

Repatha 140 mg solution for injection in pre-filled pen

The needle cover of the pre-filled pen is made from dry natural rubber (a derivative of latex), which may cause severe allergic reactions.

 

Section 4.5 Interaction with other medicinal products and other forms of interaction

No formal drug-drug interaction studies have been conducted for Repatha performed.

4.7 Effects on ability to drive and use machines

Repatha has no known or negligible influence on the ability to drive and use machines.

6.6 Special precautions for disposal and other handling

 

Before administration, the solution should be inspected. Do not inject t The solution should not be injected if it contains particles, or is cloudy or discoloured. To avoid discomfort at the site of injection, allow the medicinal product should be allowed e to reach room temperature (up to 25ºC) before injecting. Inject t The entire contents should be injected.

 

Section 10 Date of revision of the text

April 2020

Updated on 27 February 2020

File name

en_repatha_approved_pil_v38_1582803883.pdf

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Section 2. What you need to know before you use Repatha

Talk to your doctor, pharmacist or nurse before using Repatha if you have:

  • liver disease.,
  • severe kidney problems.
     
    Date of revision of the text
    November 2019 January 2020

Updated on 27 February 2020

File name

en_repatha_approved_spc_v38_1582803766.pdf

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Deleted text with strikethrough, new text in bold

 

Section 4.2 Posology and method of administration

Patients with renal impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment (see section 5.2)., see section 4.4 for patients with severe renal impairment (eGFR < 30 mL/min/1.73 m2).

 

Section 4.4 Special Warnings and Precautions

Renal impairment

There is limited experience with Repatha in patients with severe renal impairment (defined as eGFR < 30 mL/min/1.73 m2) (see section 5.2). Repatha should be used with caution in patients with severe renal impairment.

 

5.2 Pharmacokinetic properties

Renal impairment

No dose adjustment is necessary in patients with mild to moderate renal impairment. Population pharmacokinetic analysis of integrated dData from the Repatha clinical trials did not reveal a difference in pharmacokinetics of evolocumab in patients with mild or moderate renal impairment relative to non-renally impaired patients. There is limited experience with Repatha in patients with severe renal impairment (see section 4.4).

In a clinical trial of 18 patients with either normal renal function (estimated glomerular filtration rate [eGFR] ≥ 90 mL/min/1.73 m2, n = 6), severe renal impairment (eGFR 15 to 29 mL/min/1.73 m2, n = 6), or end-stage renal disease (ESRD) receiving haemodialysis (n = 6), exposure to unbound evolocumab as assessed by Cmax after a single 140 mg subcutaneous dose was decreased by 30% in patients with severe renal impairment and by 45% in patients with ESRD receiving haemodialysis.  Exposure as assessed by AUClast was decreased by approximately 24% in patients with severe renal impairment and by approximately 45% in patients with ESRD receiving haemodialysis. The exact mechanism of PK differences is unknown; however, differences in body weight could not explain these differences. Some factors including small sample size and large inter-subject variability should be considered when interpreting the results.  The pharmacodynamics and safety of evolocumab in patients with severe renal impairment and ESRD were similar to patients with normal renal function, and there were no clinically meaningful differences in LDL-C lowering.  Therefore, no dose adjustments are necessary in patients with severe renal impairment or ESRD receiving haemodialysis.

 

Section 10 Date of revision of the text

November 2019 January 2020

Updated on 27 November 2019

File name

en_repatha_approved_spc_PSURv7_1574851111.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects - Addition of hypersensitivity as a common Adverse Event

Section 10 Date of revision of the text - Updated to November 2019

Updated on 27 November 2019

File name

en_repatha_approved_pil_PSURv7_1574851041.pdf

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Free text change information supplied by the pharmaceutical company

Section 4 Side Effects - Updated to state “Allergic reactions including rash” as a common side effect

Date of revision of the text - Updated to November 2019

Updated on 16 October 2019

File name

en_repatha_approved_ pil_v33_1571220248.pdf

Reasons for updating

  • Change to section 2 - excipient warnings
  • Change to section 4 - possible side effects
  • Change to date of revision

Free text change information supplied by the pharmaceutical company

Section 2 What you need to know before you use Repatha

This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’.i.e. it is essentially ‘sodium- free’ and should not affect a sodium-controlled diet.

Section 4 Side Effects

Flu like symptoms

Date of revision of the text

September 2019

Updated on 16 October 2019

File name

en_repatha_approved_ spc_v33_1571220031.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects

Additon of Influenza-like illness as an uncommon adverse reaction

Section 10 Date of revision of teh text

September 2019

Updated on 14 August 2019

File name

en_repatha_approved_spc_v35_1565793184.pdf

Reasons for updating

  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 5.1 Pharmacodynamic properties - update to information relating to the OSLER trials

Section 10 Date of revision of the text - July 2019

Updated on 24 July 2019

File name

en_repatha_approved_spc_TAUSSIG_1563969519.pdf

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

5.1     Pharmacodynamic properties

Information relating to the TAUSSIG trial has been updated.

Information in Tables 5 and 7 relating to the TAUSSIG trial has been updated.

 

10.     DATE OF REVISION OF THE TEXT

 Date of revision has been updated to June 2019

Updated on 09 May 2019

File name

en_repatha_approved_pil_PBRER06_new images_1557310543.pdf

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to other sources of information section
  • Change to improve clarity and readability

Updated on 07 May 2019

File name

en_repatha_approved_pil_PBRER06_1557230058.pdf

Reasons for updating

  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision
  • Change to other sources of information section
  • Change to improve clarity and readability

Updated on 07 May 2019

File name

en_repatha_approved_spc_PBRER06_1557230174.pdf

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 Undesirable Effects

 

Tabulated summary of adverse reactions

Adverse reactions reported in pivotal, controlled clinical studies, and spontaneous reporting, are displayed by system organ class and frequency in table 1 below using the following convention: very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).

 

Table 1. Adverse reactions with Repatha

  • Addition of angioedema as a rare adverse reaction

 

Section 10 Date of revision of the text

April 2019

File name

en_repatha_approved_pil_v17.pdf

Updated on 29 May 2018

File name

en_repatha_approved_pil_v17.pdf

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 29 May 2018

File name

en_repatha_approved_smpc_ireland_v17.docx

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Addition of new indication "Established atherosclerotic cardiovascular disease" and subsequently changes made to sections 4.2, 5.1 and 5.2

Changes to section 4.4 regarding patients with renal impairment

Changes to section 4.8 injection site reactions

Updated on 21 May 2018

File name

en_repatha_approved_smpc_ireland_v17.docx

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.1 Therapeutic indications

Addition of new indication Established atherosclerotic cardiovascular disease

 4.2 Posology and method of administration

Update to the posology sub-section with information on Established atherosclerotic cardiovascular disease in adults

4.4 Special Warnings and Precautions

Update to the renal impairment sub-section

4.8 Undesirable Effects

Update to the Summary of the safety profile, Injection site reactions, Elderly population and Immunogenicity sub-sections

5.1 Pharmacodynamic properties

Update to the Clinical efficacy in primary hypercholesterolaemia and mixed dyslipidaemia sub-section

 

New information - Effect on atherosclerotic disease burden & Cardiovascular risk reduction in adults with established atherosclerotic cardiovascular disease

Section 5.2 Pharmacokinetic properties

Update to sub section renal impairment

10 Date of revision of the text

May 2018

Updated on 18 May 2018

File name

en_repatha_approved_pil_v17.pdf

Reasons for updating

  • Change to Section 1 - what the product is
  • Change to section 1 - what the product is used for
  • Change to section 3 - how to take/use
  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 11 March 2018

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Updated on 11 March 2018

Reasons for updating

  • Change to section 6.3 - Shelf life
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

 

The shelf life of the Repatha® pre-filled syringe and the Repatha® pre-filled pen (SureClick®) has been extended to 3 years. 

Please note that the Repatha® pre-filled syringe is not marketed in Ireland


Section 6.3 Shelf life

Repatha 140 mg solution for injection in pre-filled syringe
3 years.

Repatha 140 mg solution for injection in pre-filled pen
3 years.

Repatha 420 mg solution for injection in cartridge
2 years.

Section 10. DATE OF REVISION OF THE TEXT

Updated to March 2018

Updated on 11 April 2017

File name

PIL_16434_184.pdf

Reasons for updating

  • New PIL for new product

Updated on 11 April 2017

Reasons for updating

  • Change to section 6 - manufacturer

Updated on 24 February 2017

Reasons for updating

  • Change to section 10 - Date of revision of the text
  • Change from individual to joint SPC

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



 

The Repatha Summary of Product Characteristics has been updated to now incorporate three presentations:

 

1)         Solution for injection in pre-filled syringe

2)         Solution for injection in pre-filled pen (SureClick)

3)         Solution for injection in cartridge (automated mini-doser)

 

Please note that the Repatha solution for injection in pre-filled syringe and cartridge (automated mini-doser) are not available in Ireland.

Updated on 24 February 2017

Reasons for updating

  • Change to section 6 - date of revision

Updated on 30 September 2016

Reasons for updating

  • Change to section 6.4 - Special precautions for storage
  • Change to section 10 - Date of revision of the text

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The following sections of the SmPC have been updated:

 

Section 6.4 Special precautions for storage:

 

Previous text:

If removed from the refrigerator, Repatha may be stored at room temperature (up to 25°C) in the original carton and must be used within 1 week.

 

New text:

If removed from the refrigerator, Repatha may be stored at room temperature (up to 25°C) in the original carton and must be used within 1 month.

 

 

10.    DATE OF REVISION OF THE TEXT

Previous text:

July 2015

 

New text:

September 2016

Updated on 30 September 2016

Reasons for updating

  • Change to storage instructions
  • Change to date of revision

Updated on 29 June 2016

Reasons for updating

  • Change to further information section
  • Change to date of revision

Updated on 31 July 2015

Reasons for updating

  • New SPC for new product

Legal category:Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 31 July 2015

Reasons for updating

  • New PIL for new product